NEUROCRINE BIOSCIENCES INC Shareholders' Equity
NEUROCRINE BIOSCIENCES INC (NBIX) had Shareholders' Equity of $3.69 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-31
- 2026-06-30: Stockholders' Equity Attributable to Parent $3.69B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $3.41B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $3.25B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.00B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $3.69B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $3.41B 10-Q · filed 2026-07-31 | |
| 2025-12-31 | $3.25B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $3.00B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $2.69B 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $2.54B 10-Q · filed 2026-07-31 | |
| 2024-12-31 | $2.59B 10-Q · filed 2026-07-31 | |
| 2024-09-30 | $2.72B 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $2.51B 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $2.39B 10-Q · filed 2025-07-30 | |
| 2023-12-31 | $2.23B 10-K · filed 2026-02-11 | |
| 2023-09-30 | $2.00B 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $1.85B 10-Q · filed 2024-10-30 | |
| 2023-03-31 | $1.68B 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $1.71B 10-K · filed 2026-02-11 | |
| 2022-09-30 | $1.54B 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $1.42B 10-Q · filed 2023-10-31 | |
| 2022-03-31 | $1.39B 10-Q · filed 2023-08-01 | |
| 2021-12-31 | $1.37B 10-K · filed 2025-02-10 | |
| 2021-09-30 | $1.35B 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $1.28B 10-Q · filed 2022-11-01 | |
| 2021-03-31 | $1.21B 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $1.13B 10-K · filed 2024-02-09 | |
| 2020-09-30 | $804.30M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $831.20M 10-Q · filed 2021-11-01 | |
| 2020-03-31 | $700.30M 10-Q · filed 2021-08-03 | |
| 2019-12-31 | $636.90M 10-K · filed 2023-02-09 | $636.92M 10-K · filed 2020-02-07 |
| 2019-09-30 | $574.50M 10-Q · filed 2020-11-09 | $574.51M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $483.70M 10-Q · filed 2020-11-09 | $483.71M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $409.30M 10-Q · filed 2020-08-03 | $409.27M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $480.80M 10-K · filed 2022-02-11 | $480.76M 10-K · filed 2019-02-08 |
| 2018-09-30 | $447.51M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $377.44M 10-Q · filed 2019-11-04 | |
| 2018-03-31 | $364.49M 10-Q · filed 2019-11-04 | |
| 2017-12-31 | $372.20M 10-K · filed 2021-02-05 | $372.14M 10-K · filed 2018-02-13 |
| 2017-09-30 | $347.51M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $345.24M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $247.14M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $314.88M 10-K · filed 2020-02-07 | |
| 2016-09-30 | $351.65M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $381.04M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $412.96M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $424.45M 10-K · filed 2019-02-08 | |
| 2015-09-30 | $446.94M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $466.94M 10-Q · filed 2015-07-29 | |
| 2015-03-31 | $484.73M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $208.70M 10-K · filed 2018-02-13 | |
| 2014-09-30 | $224.04M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $236.84M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $247.06M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $120.41M 10-K · filed 2017-02-14 | |
| 2013-09-30 | $129.29M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $136.02M 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $144.95M 10-Q · filed 2013-05-02 | |
| 2012-12-31 | $154.37M 10-K · filed 2016-02-11 | |
| 2012-09-30 | $143.31M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $144.73M 10-Q · filed 2012-07-31 | |
| 2012-03-31 | $143.83M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $60.08M 10-K · filed 2015-02-09 | |
| 2011-09-30 | $57.75M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $25.56M 10-Q · filed 2011-07-29 | |
| 2010-12-31 | $19.34M 10-K · filed 2014-02-11 | |
| 2009-12-31 | $3.95M 10-K · filed 2013-02-08 | |
| 2008-12-31 | $36.77M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |